Platinum-free interval affects efficacy of following treatment for platinum-refractory or -resistant ovarian cancer

ConclusionsPS 1 –2 and PFI <  3 months were significant predictors of poor response to following treatment for PRROC. Risks and benefits of treatment should be frankly discussed with patients who have these characteristics.
Source: Cancer Chemotherapy and Pharmacology - Category: Cancer & Oncology Source Type: research